Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection  by Einarsdóttir, H.M. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01221.x
Nationwide study of recurrent invasive pneumococcal infections in a
population with a low prevalence of human immunodeficiency virus
infection
H. M. Einarsdo´ttir1, H. Erlendsdo´ttir2, K. G. Kristinsson2,3 and M. Gottfredsson1,3
Departments of 1Internal Medicine and 2Clinical Microbiology, Landspı´tali University Hospital and
3University of Iceland, Reykjavı´k, Iceland
ABSTRACT
Recurrent invasive infections caused by Streptococcus pneumoniae are rare, and often considered to be
indicative of serious underlying illness. However, the prevalence of this problem, and the relevance of
specific predisposing conditions, can be hard to assess, since many of the studies are based on specific
risk groups. A population-based study of recurrent invasive pneumococcal disease in Iceland during the
30-year period 1975–2004 was performed. Clinical information, including mortality and vaccine use, was
analysed retrospectively. Invasive pneumococcal isolates were serotyped and susceptibility testing was
performed. During this period, 36 (4.4%) of 819 patients who survived an initial infection experienced
recurrence, with a median time between episodes of 9.7 months. Pneumonia with bacteraemia was the
most common clinical diagnosis (48% of cases), followed by bacteraemia without a clear focus (21%)
and meningitis (13%). Most (94%) of the patients had identifiable predisposing conditions, most
commonly, multiple myeloma in adults, and antibody deficiencies in children. Compared with children,
adults were more likely to present with pneumonia (65% vs. 18%; p 0.0001). No significant change in
the 30-day mortality rate was observed during the three decades of the study. Only 26% of eligible
patients received pneumococcal vaccination. Patients with recurrent invasive pneumococcal disease
should be investigated thoroughly for underlying diseases. Greater use of pneumococcal vaccines
should be encouraged among high-risk patients. More effective preventive and therapeutic measures are
needed to improve outcomes.
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INTRODUCTION
Infections caused by Streptococcus pneumoniae are
common, and invasive infections, such as bacter-
aemia and meningitis, caused by this organism
are associated with high rates of morbidity and
mortality [1,2]. Although the incidence of pneu-
mococcal disease is increasing in some countries
[3,4], the use of a seven-valent pneumococcal
conjugate vaccine in a childhood vaccination
programme in the USA has reduced the rate of
invasive pneumococcal disease in both children
and adults [5]. Many risk-factors for pneumococ-
cal infection have been well-established, such as
antibody deficiencies [6,7], defective antibody
formation [8], complement deficiencies [9], asple-
nia [10], age (higher likelihood with extremes of
age) [3], malnutrition [11], alcoholism [12,13],
tobacco use [14], infection with human immuno-
deficiency virus (HIV) [15–18], renal insufficiency
[19] and chronic disease [20].
Recurrent invasive pneumococcal disease has
been described in numerous case reports and case
series [21–31]. It has been stated that recurrence is
a rare event [20,26–28], with a documented risk of
2.3–5.3% [17,26–28]. Recurrence is often consid-
ered to be a strong indicator of serious underlying
illness [26,28], with a mortality rate as high as
47% during the recurrent episode [26], although
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the significance of these recurrences may depend,
in part, on the age of the patient. One study found
that recurrent invasive pneumococcal infections
in young children did not indicate the presence of
an unsuspected immunodeficiency [29]. Similarly,
one case series described five children with
recurrent invasive pneumococcal disease, two of
whom had no detectable underlying disease [30].
Thus, the prevalence of various conditions that
predispose to recurrent pneumococcal infections
may be highly age-dependent. However, studies
of this clinical entity have been limited by small
patient numbers, short follow-up periods, and a
primary focus on selected patient populations
such as children and individuals with HIV infec-
tion [26,28,31].
The aim of the present study was to investigate
the epidemiological trends, clinical characteristics
and microbiological findings among children and
adults with recurrent invasive pneumococcal
infections in Iceland during a 30-year period.
Because the annual incidence of HIV infection in
Iceland is low, it was possible to assess the
contributions of other risk-factors to recurrent
disease.
PATIENTS AND METHODS
Setting and patient selection
Iceland is an island in the mid-Atlantic ocean, with a
population that increased from 219 033 at the end of 1975
to 293 291 by the end of 2004. The socio-economic status is
high and the inhabitants have universal access to a govern-
ment-based healthcare system. The country has two univer-
sity or university-affiliated hospitals and 14 county hospitals,
as well as numerous smaller health clinics. All hospitals and
clinics were included in this study. Blood cultures were
processed at two or three sites in the country, and a single
reference laboratory performed serotyping on all invasive S.
pneumoniae isolates. All patients, adults and children (aged
£ 16 years), with pneumococci cultured from blood, cerebro-
spinal fluid, joint fluid or peritoneal fluid, or patients with a
positive Gram-stain cerebrospinal fluid smear and a positive
latex agglutination test for pneumococci, were recorded in an
electronic database that was used to identify recurrences.
Definitions
Individuals at risk of recurrent invasive pneumococcal
disease were those who survived for 30 days after the initial
episode of infection [17]. Recurrent pneumococcal disease
was defined as two or more episodes of invasive pneumo-
coccal infection separated by > 4 weeks, or episodes separ-
ated by < 4 weeks but caused by different pneumococcal
serotypes, during a 30-year period (1 January 1975 to 20
September 2004).
Data registration
The following clinical data were collected by chart review: age,
gender, socio-economic status, tobacco use, alcohol consump-
tion and vaccination status. Each episode of infection was
reviewed to determine the type of infection, presenting signs,
previous medication, physical examination, complete blood
count and biochemical profile, treatment and diagnosis at
discharge. Results of radiological, immunological and histo-
pathological investigations, including autopsies, were docu-
mented. The numbers and types of bacterial cultures were
documented. Outcome (mortality at 30 days) was calculated
from hospital charts and the national population register.
Microbiology
Serotyping of available invasive isolates was performed by
coagglutination with antisera from the Statens Serum Institute
(Copenhagen, Denmark). The invasive isolates were screened
for penicillin resistance by the oxacillin disk-diffusion test [32].
Penicillin MICs were determined for all oxacillin-resistant
isolates by Etest (AB Biodisk, Solna, Sweden). Isolates with a
penicillin MIC ‡ 0.1 mg ⁄L were defined as penicillin non-
susceptible. Four patients had two separate infections with the
same pneumococcal serotype; six of these eight isolates were
available for DNA fingerprinting by pulsed-field gel electro-
phoresis following DNA restriction with SmaI [33].
Statistical analysis
The chi-square test was used for statistical comparison of the
incidence of recurrence during the two halves of the study
period. Fisher’s exact test was used for comparison of types of
infection among adults and children. Statistical significance
was set at p < 0.05. All tests were two-tailed.
Ethical approval
The study was approved by the National Bioethics Committee
of Iceland and the Data Protection Authority of Iceland.
RESULTS
Epidemiology
Invasive pneumococcal infections were diagnosed
in 933 patients during the study period. Of these
933 patients, 819 survived for > 30 days after the
initial episode, and 36 (4.4%) of the survivors had
one or more invasive pneumococcal infections
subsequently (total of 77 episodes). These 36
patients included 12 children with 28 infections
(primary and recurrent), and 24 adults with 49
infections. The median ages of children and adults
were 2.5 years and 65.3 years, respectively. The
mean time between episodes was 15.4 months,
with a median of 9.7 months (range, 15 days to
7.7 years). Two patients had infections separated
by < 1 month, but with different pneumococcal
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serotypes. Three patients had three episodes of
infection, and one patient had four episodes. The
overall incidence rate of invasive pneumococcal
disease during the first half of the study periodwas
8.3 cases ⁄ 100 000 inhabitants ⁄ year, which doubled
to 16.7 cases ⁄ 100 000 inhabitants ⁄year during the
second half. Concurrently, the incidence of
recurrent disease increased from 0.37
recurrences ⁄ 100 000 inhabitants ⁄ year to 0.76
recurrences ⁄ 100 000 inhabitants ⁄year (p 0.04).
Thus, the recurrence rates remained unchanged
(4.3% and 4.4%, respectively) during the first and
second halves of the study period.
Clinical characteristics
Table 1 summarises the clinical presentations of
the two age groups. Overall, bacteraemic pneu-
monia was the most common clinical presentation
(48% of cases), followed by bacteraemia without a
clear focus (20.8%) and meningitis (13%). Adults
were more likely to have bacteraemic pneumonia
(p 0.0001), whereas children were more likely to
have bacteraemia ⁄ sepsis without a specific focus
(p 0.063) and meningitis (p 0.096).
The risk-factors of the 36 patients are shown in
Table 2. All but two had one or more underlying
diseases. Recurrent pneumococcal infection was
the presenting manifestation of the underlying
disease in seven (58%) of the 12 children. The
most common disease in this group was IgG-
subclass deficiency and ⁄ or a poor antibody
response (dysglobulinaemia) to antigenic stimuli.
Among the 24 adults, immunoglobulin disorders
were also the most common predisposing factors,
with multiple myeloma present in six, monoclo-
nal gammopathy in two, leukaemia in three, and
HIV ⁄AIDS in two patients. One child and two
adults were affected by renal disease.
Microbiology
Antibiograms were available for isolates causing
67 (86%) of the episodes. Two (3%) of these 67
isolates were multiresistant (serotypes ⁄groups 6B
and 9). All other isolates were susceptible to
penicillin. Serogroups or serotypes of invasive
isolates were determined for 45 (58%) of 78
infections (Table 3). The serotypes of the isolates
from both the initial and recurrent episodes were
known for 18 patients. Of these, four (22%) had
identical serogroups and DNA fingerprints. The
remaining 14 (78%) isolates belonged to different
serotypes.
Outcomes
The 30-day mortality rate for adults was 25%; no
childrendiedduring this period. Themortality rate
for meningitis was 25%, and that for non-menin-
gitic episodes was 11%. No difference in mortality
rates was noted between the first and second
halves of the study period (data not shown).
DISCUSSION
The incidence of invasive pneumococcal disease
is increasing in some countries [3,4]. In Iceland,
the overall incidence doubled during the 30-year
Table 1. Clinical diagnoses of children (aged < 16 years)
and adults (aged ‡ 16 years) with recurrent invasive
pneumococcal infections
Diagnosis
Children,
n (%)
Adults,
n (%) p
Bacteraemic pneumoniaa 5 (18) 32 (65) 0.0001
Bacteraemia without focus 9 (32) 7 (14) 0.063
Meningitisb 6 (21) 4 (8) 0.096
Peritonitisc 3 (11) 2 (4) ND
Septic arthritis 1 (4) 1 (2) ND
Bacteraemia and cellulitis 1 (4) 1 (2) ND
Bacteraemia and otitis media 2 (7) 1 (2) ND
Bacteraemia and sinusitis 1 (4) 0 ND
Osteomyelitis 0 1 (2) ND
Total number of episodes 28d 49d
aOne child also had sinusitis.
bOne child also had sinusitis, and one also had otitis media.
cOne child also had pneumonia.
dPercentages do not add up to 100% because of rounding.
ND, not calculated.
Table 2. Underlying illness or risk-factors among children
(aged < 16 years) and adults (aged ‡ 16 years) with
recurrent invasive pneumococcal infections
Underlying disease Children, n (%) Adults, n (%)
Immunoglobulin disordersa 6b (50) 13 (54)
Renal diseasesc 1 (8) 2 (8)
Asplenia 1 (8) 1 (4)
Anatomical defectd 3 (25)
Other conditionse – 7 (29)
No known risk condition 1 (8) 1 (4)
Vaccinationf 4 ⁄ 7 (57) 2 ⁄ 16 (13)
Total number of patients 12 24
aHypo ⁄dysgammaglobulinaemia; multiple myeloma; monoclonal gammopathy;
amyloidosis; leukaemia; infection with human immunodeficiency virus ⁄AIDS.
bTwo children (aged 6 and 20 months) had low pneumococcal antibodies; three
children had immunoglobulin deficiencies; one child had leukaemia.
cChronic renal failure; nephrotic syndrome.
dMeningocele with pansinusitis; extensive lymphangioma; Turner’s syndrome with
coarctation of aorta and asthma.
eAlcoholism; chronic obstructive pulmonary disease; solid tumour; malnutrition.
fNumber of patients, infected after 1991, who received pneumococcal vaccination
either before or after the infection.
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period of this study. Clearly, incidence rates
depend heavily on a variety of factors, including
the availability of diagnostic tests and their
appropriate use. In addition, the sensitivity and
specificity of the tests are of major importance.
Other potential explanations for this increase
include a greater population at risk, the introduc-
tion of more invasive ⁄virulent pneumococcal
clones into the population, a loss of herd immu-
nity, changes in environmental factors, such as
smoking and air pollution, and severe virus
infections, such as influenza, that predispose to
pneumococcal infections. Among these potential
explanations, improved detection probably plays
a large role.
Published case reports and case series of
recurrent pneumococcal infections [21–31] are
limited by relatively few and ⁄ or selected patients
and short follow-up periods. In the present study,
an unselected population of children and adults
was analysed for a 30-year period. King et al. [17]
published a large population-based study of
recurrent pneumococcal disease in the USA, but
44% of their 318 patients had HIV infection.
Iceland has a low incidence of HIV infection
(3 ⁄ 100 000 inhabitants ⁄year), thereby allowing
the contribution of other underlying diseases to
the risk of recurrent invasive pneumococcal dis-
ease to be assessed.
The likelihood of recurrent pneumococcal dis-
ease was found to be 4.4%, a result similar to that
reported by most other studies [17,25–29,31],
although a recurrence rate as low as 0.6% has
also been reported [20]. Interestingly, this rate of
recurrent disease in a population with few cases
of HIV infection was similar to the rate of 5.3%
reported by Turett et al. [27] in a population with
a high prevalence of HIV infection. The recur-
rence rate in the present population remained
stable during the 30-year study period, but the
incidence of recurrent disease doubled, as did
the incidence of invasive pneumococcal disease in
the population as a whole.
In children, the most common risk-factor for
recurrent pneumococcal disease was poor anti-
body formation after polysaccharide antigenic
stimuli and Ig-subclass deficiencies. Patients with
recurrent infections associated with defective
antibody responses should be followed periodic-
ally, since this can be either a transient phenom-
enon related to an immature immune system, or a
persistent selective impaired response [34].
The most common underlying diseases in
adults were multiple myeloma and related disor-
ders, accompanied by dysgammaglobulinaemia.
Unlike the situation with children, only one adult
was found to have a previously undiagnosed
disease.
As reported previously [17,25], most (78%)
patients were infected with different pneumococ-
cal serotypes in the initial and recurrent episodes.
Non-susceptibility to penicillin (MIC ‡ 0.1 mg ⁄L)
was found in only 3% of the isolates in the
present study, a rate much lower than the rate of
12.4% found by King et al. [17] in the USA.
However, the results are not entirely comparable,
since penicillin resistance appeared in pneumo-
cocci in Iceland only in the late 1980s [33], and the
period of the present study extended back to 1975.
Nevertheless, these differences do reflect the more
rapid spread of penicillin-non-susceptible pneu-
mococci in the USA, which reached a frequency of
35.4% in 2002 [35], compared with 11% in Iceland
[36]. The overall mortality rate of 17% associated
with recurrent infections was similar to that of
unselected patients with invasive pneumococcal
disease [4], and was in good agreement with the
results of Turett et al. [27].
Recommendations for vaccination with the
23-valent pneumococcal polysaccharide vaccine
were introduced in Iceland in 1991, but only six
(26%) of 22 patients who were infected after that
date had been vaccinated. Children were more
Table 3. Serotypes and serogroups of invasive pneumo-
coccal isolates from children (aged < 16 years) and adults
(aged ‡ 16 years) with 77 episodes of infection
Serogroups ⁄ types Children, n (%) Adults, n Total, n (%)
4 – 1 (4) 1 (2)
6 – 3 (12) 3 (7)
6A – 1 (4) 1 (2)
6B 2 (11) 1 (4) 3 (7)
7F 1 (5) 1 (4) 2 (4)
9 – 1 (4) 1 (2)
9N – 1 (4) 1 (2)
9V 1 (5) 1 (4) 2 (4)
11 – 1 (4) 1 (2)
14 4 (21) 2 (8) 6 (13)
16 1 (5) 1 (4) 2 (4)
17 – 1 (4) 1 (2)
18C 1 (5) 1 (4) 2 (4)
19A 2 (11) – 2 (4)
19C – 1 (4) 1 (2)
19F 2 (11) 1 (4) 3 (7)
22 0 2 (8) 2 (4)
23F 2 (11) 2 (8) 4 (9)
31 – 1 (4) 1 (2)
33 3 (16) 1 (4) 4 (9)
38 0 2 (8) 2 (4)
Total 19 (101)a 26 (104)a 45 (96)a
aPercentages do not add up to 100% because of rounding.
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likely than adults to receive the vaccine. Thirty-
eight (84.4%) of the 45 known serogroups or
serotypes detected in the present study are
included in the 23-valent vaccine. Unfortunately,
underuse of the 23-valent pneumococcal vaccine
is still widespread [37].
Recurrent invasive pneumococcal infection in a
child should prompt a thorough search for an
underlying illness, but the underlying disease in
adults is usually already known. Despite the
availability of preventive measures, such as
pneumococcal vaccination, antibiotic prophylaxis
and administration of immunoglobulins, the pro-
portion of patients with recurrent pneumococcal
infections has remained stable and the mortality
rate has not changed in Iceland during the past
three decades. Improved compliance with vaccin-
ation guidelines should be encouraged.
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